# Seawolf Therapeutics funding rounds and investors

As of 19 Nov 2026, Seawolf Therapeutics has 1 verified round on record, none with a disclosed amount; latest: $100M financing total Series A, announced Nov 2026.

A provider of a proprietary LNP-based DNA delivery platform

Website: https://www.seawolftx.com  
Headquarters: San Diego, CA  
Page: https://fireround.dev/companies/seawolf-therapeutics-3

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11 | Series A | undisclosed | not stated | Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly, MPM BioImpact, Novartis, Pathway to Cures, Sixty Degree Capital, Versant Ventures | [seawolftx.com](https://seawolftx.com/seawolf-therapeutics-debuts-with-100-million-to-advance-dna-based-therapeutics), [businesswire.com](https://www.businesswire.com/news/home/20261116723769/en/Seawolf-Therapeutics-Debuts-With-%24100-Million-to-Advance-DNA-Based-Therapeutics), [biospace.com](https://www.biospace.com/press-releases/seawolf-therapeutics-debuts-with-100-million-to-advance-dna-based-therapeutics) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
